RxDoctor Payments Data

Phuong Nguyen

Psychiatry · Marrero, LANPI 1356431761

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 633 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,149in general payments, 2019–2025

Across 633 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$828
  • Otsuka America Pharmaceutical, Inc.$827
  • Alkermes, Inc.$791
  • Lundbeck LLC$578
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$11,140100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,149 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$95,128
VraylarCariprazine Hcl12$17,748
AuvelityDextromethorphan Hbr/Bupropion11$11,547
Lisdexamfetamine Dimesylate15$4,116
Duloxetine Hcl111$3,375
Bupropion XlBupropion Hcl92$2,345
Venlafaxine Hcl ErVenlafaxine Hcl83$2,011
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$1,862
Divalproex Sodium ErDivalproex Sodium24$1,436
Mirtazapine75$1,048
Aripiprazole30$837
Methylphenidate Hcl34$814
Olanzapine25$752
Trazodone Hcl80$734
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$40$95,12812 claims
AbbVieVraylar$2,354$17,74812 claims
Axsome Therapeutics, Inc.Auvelity$399$11,54711 claims
Lilly USA, LLCOlanzapine$48$75225 claims
Almatica Pharma LLCSertraline Hcl$388$33649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →